SmartCells Inc.
This article was originally published in Start Up
Executive Summary
SmartCells' SmartInsulin is a once-daily subcutaneous injectable formulation of insulin for the treatment of type 1 and type 2 diabetes. SmartInsulin comprises insulin molecules conjugated to a biocompatible and biodegradable polymer, which binds to a multivalent glucose-binding molecule. Once injected, it self-assembles to form an insoluble matrix. Insulin is released from the system only when the therapeutic is unbound by the presence of a specific glucose concentration.
You may also be interested in...
Start-Up Previews
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Antibiotics Start-Ups," features profiles of Indel Therapeutics, MicuRx Pharmaceuticals and Trius Therapeutics. Plus these Start-Ups Across Health Care: DFine, NexeonMedSystems, SmartCells and Somnus Therapeutics.
Start-Up Previews
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Antibiotics Start-Ups," features profiles of Indel Therapeutics, MicuRx Pharmaceuticals and Trius Therapeutics. Plus these Start-Ups Across Health Care: DFine, NexeonMedSystems, SmartCells and Somnus Therapeutics.
Will Simpler Devices Tap the Largest Diabetes Market?
The clinical community and the medical device industry are finally turning their attention to the majority of patients with diabetes: the type 2s. They're an underserved group in a potential market that dwarfs that of type 1 diabetes. Health Advances LLC believes that the next disruptive technology in diabetes management will come in the form of lower-cost, easy-to-use insulin pumps for the masses. And there are at least 16 such pumps in development. (See also the sidebar, CeQur: Conforming to the Lifesyle of the Type 2).